New data on ocrelizumab and satralizumab-mwge will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 13 – 15, 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both ocrelizumab and satralizumab, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations could help ensure access to treatment.

Multiple sclerosis (MS)

Genentech will present 27 MS studies, including long-term data that show earlier treatment with ocrelizumab continues to impact disability progression up to 8 years in people with primary progressive multiple sclerosis (PPMS) and up to 7.5 years in people with relapsing multiple sclerosis (RMS) in the Phase III open label extension (OLE) studies. Additionally, updated long-term safety analysis of all clinical trials in patients with RMS and PPMS will reinforce the consistently favorable benefit-risk profile of ocrelizumab.

A subgroup analysis of three studies (SaROD, CHORDS and ENSEMBLE PLUS) in Black, African-American, Hispanic and Latino populations treated with a 2-hour ocrelizumab infusion will also be presented.

Neuromyelitis optica spectrum disorder (NMOSD)

New longer-term results from the SAkuraStar and SAkuraSky OLE studies for satralizumab will show efficacy observed in the pivotal trials is sustained with high proportions of patients remaining free from relapse over four years of treatment. Similarly, safety data from the SAkuraStar and SAkuraSky OLE studies will show the favorable safety profile of satralizumabis sustained with longer-term treatment. satralizumab has been approved in 58 countries globally, including in the U.S. as the first and only subcutaneous treatment for adults with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD. satralizumabhas also been approved for both adults and adolescents in the European Union, Japan, Canada and Switzerland.

The study design will be presented for SAkuraBONSAI, a prospective, open-label study of satralizumabto generate data to further the understanding of the disease activity and mechanism of action of satralizumab in patients living with AQP4-IgG seropositive NMOSD who are treatment naïve or where prior rituximab (or biosimilar) treatment has failed. Other presentations will examine the development of new tools and techniques to identify patients with NMOSD and assess disability better.